PMID- 16405895
OWN - NLM
STAT- MEDLINE
DCOM- 20070105
LR  - 20220410
IS  - 0021-9150 (Print)
IS  - 0021-9150 (Linking)
VI  - 188
IP  - 2
DP  - 2006 Oct
TI  - Plasma interleukin (IL)-18 concentrations is elevated in patients with previous 
      myocardial infarction and related to severity of coronary atherosclerosis 
      independently of C-reactive protein and IL-6.
PG  - 450-4
AB  - AIM: Interleukin-18 (IL-18) is a pro-inflammatory cytokine with a central role in 
      the inflammatory cascade. In the present study, we investigated whether patients 
      with precocious myocardial infarction have higher plasma IL-18 concentrations 
      than matched controls. Furthermore, the relationships between plasma IL-18 
      concentrations and coronary atherosclerosis, C-reactive protein (CRP), 
      interleukin-6 (IL-6) and traditional cardiovascular risk factors were examined. 
      METHODS AND RESULTS: Three hundred eighty-seven unselected survivors of a first 
      myocardial infarction aged less than 60 years and 387 sex and age matched 
      controls were enrolled in the study. A subset of patients (n=236) was evaluated 
      by quantitative coronary angiography. Postinfarction patients had significantly 
      higher mean level of plasma IL-18 than controls (309.6+/-138.6 versus 
      285.4+/-115.7pg IL-18/mL). Furthermore, plasma IL-18 concentration was 
      significantly associated with coronary plaque area (r=0.17, p=0.009). This 
      relationship remained in a partial correlation analysis adjusting for CRP 
      (r=0.15, p=0.02), for IL-6 (r=0.15, p=0.02) and for both CRP and IL-6 (r=0.15, 
      p=0.02). In addition, IL-18 levels were significantly associated with other 
      cardiovascular risk factors, namely age, low density lipoprotein (LDL) 
      cholesterol, triglycerides, high density lipoprotein (HDL) cholesterol, insulin, 
      proinsulin, body mass index (BMI), systolic and diastolic blood pressure. 
      CONCLUSION: The present work provides evidence that plasma IL-18 is increased in 
      postinfarction patients and is associated with coronary atherosclerosis.
FAU - Hulthe, Johannes
AU  - Hulthe J
AD  - Discovery Medicine, AstraZeneca, Molndal, Sweden; Wallenberg Laboratory for 
      Cardiovascular Research, Sahlgrenska University Hospital, Gothenburg, Sweden. 
      Johannes.Hulthe@astrazeneca.com
FAU - McPheat, William
AU  - McPheat W
FAU - Samnegard, Ann
AU  - Samnegard A
FAU - Tornvall, Per
AU  - Tornvall P
FAU - Hamsten, Anders
AU  - Hamsten A
FAU - Eriksson, Per
AU  - Eriksson P
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060106
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - 0 (Insulin)
RN  - 0 (Interleukin-18)
RN  - 0 (Interleukin-6)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
CIN - Atherosclerosis. 2007 Dec;195(2):415-6. PMID: 17499253
MH  - Age Factors
MH  - Blood Pressure
MH  - Body Mass Index
MH  - C-Reactive Protein/*analysis
MH  - Cholesterol/blood
MH  - Coronary Angiography
MH  - Coronary Artery Disease/*blood
MH  - Female
MH  - Humans
MH  - Insulin/blood
MH  - Interleukin-18/*blood
MH  - Interleukin-6/*blood
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*blood
MH  - Nephelometry and Turbidimetry
MH  - Risk Factors
MH  - Sweden
EDAT- 2006/01/13 09:00
MHDA- 2007/01/06 09:00
CRDT- 2006/01/13 09:00
PHST- 2005/05/24 00:00 [received]
PHST- 2005/10/19 00:00 [revised]
PHST- 2005/11/08 00:00 [accepted]
PHST- 2006/01/13 09:00 [pubmed]
PHST- 2007/01/06 09:00 [medline]
PHST- 2006/01/13 09:00 [entrez]
AID - S0021-9150(05)00765-3 [pii]
AID - 10.1016/j.atherosclerosis.2005.11.013 [doi]
PST - ppublish
SO  - Atherosclerosis. 2006 Oct;188(2):450-4. doi: 
      10.1016/j.atherosclerosis.2005.11.013. Epub 2006 Jan 6.